Omicron variant – Page 15 – Communicable Diseases Research

Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2

Article

Published on 2022-12-012022-11-16
Journal: Journal of molecular graphics & modelling [Category] COVID19(2023년), SARS, 변종, 치료기술,

Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants

Article

Published on 2022-12-012023-07-10
Journal: The Journal of Infection [Category] COVID19(2023년),

[키워드] ACE2 COVID-19 GRP78 Omicron variant SARS-CoV-2 recognition spike RBD
[DOI] 10.1016/j.jinf.2022.10.009 PMC 바로가기

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants

비강 오미크론 백신 부스터는 새로운 SARS-CoV-2 변이체에 대한 강력한 중화 항체 반응을 이끌어냅니다.

Article

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] absence adjuvants administration antibody Antibody Response boost booster Bronchoalveolar lavage caused clinical trial composed COVID-19 COVID-19 pandemic current deaths delta variant described disease severity domain dose effective Elevation elicit evidenced FIVE fused human infection human infections humans IgA Immunity immunogen intranasal leads mice MOST mucosal nasal nasal protein vaccine booster Neutralizing activity neutralizing antibody Neutralizing antibody response omicron Omicron variant Protein Receptor binding domain reduce respiratory SARS-CoV-2 SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 transmission SARS-CoV-2 variant severity significantly single dose suggested the antibody response the disease vaccination Vaccine virus infection wild-type
[DOI] 10.1080/22221751.2022.2053365 PMC 바로가기 [Article Type] Article

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants

고처리량 포화 돌연변이 유발에 의해 생성된 ACE2 미끼 수용체는 SARS-CoV-2 및 그 유행하는 변이체를 효율적으로 중화합니다

Article

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종,

[키워드] ACE2 ACE2 binding ACE2-RBD binding approach binding binding affinity C-terminal cellular receptor changes in convalescent sera Critical critical point D614G decoy receptor domain Effect fused global pandemic glycosylation site High-throughput screening increase in Microarray monoclonal antibodies Mutagenesis mutations neutralization neutralize neutralized Omicron variant Point mutation prevalent protease Protein protein engineering Pseudotyped virus RBD RBD binding RBD-ACE2 receptor Receptor binding domain rescued SARS-CoV-2 SARS-CoV-2 virus significantly single-cell soluble ACE2 Spike protein the SARS-CoV-2 the SARS-CoV-2 virus therapeutic potential Treatment Vaccine variant variants viral entry viral spike protein wild-type
[DOI] 10.1080/22221751.2022.2079426 PMC 바로가기 [Article Type] Article

Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination

Article

Published on 2022-12-012022-11-15
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé omicron Omicron variant overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured
[DOI] 10.1002/jmv.28044 PMC 바로가기

SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2

Article

Published on 2022-12-012022-11-16
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종,

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

SARS-CoV-2 융합 억제 리포펩티드는 오미크론을 포함한 다양한 관심 변종에 대해 높은 효능을 유지합니다

Article

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 치료제,

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험

Clinical Trial

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단,

[키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed
[DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial

Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers

Article

Published on 2022-12-012022-11-15
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단,

[키워드] AstraZeneca Biomarker booster case-control study caused Chronic diseases Clinical severity conducted country COVID-19 COVID-19 confirmed patient COVID-19 patient COVID-19 vaccination COVID-19 vaccine CRP level Delta delta variant Delta wave dose doses effective Effectiveness Efficacy expressed females Health homologous Homologous vaccination hospital Hospitalization Hospitalized individual infected with SARS-CoV-2 Iraq Lower males molecular no significant difference no significant effect omicron Omicron variant pandemic Patient patients Pfizer Population Prevent recommendation recorded risk SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severity significantly Symptom the disease the vaccine transmissibility of SARS-CoV-2 vaccination Vaccine variant variants of concern virus VOCs was done WBC
[DOI] 10.1002/jmv.28098 PMC 바로가기

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity

COVID-19 회복기에 대한 1년 종단 연구는 항 SARS-CoV-2 체액성 및 세포성 면역의 지속성을 보여줍니다

Article

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] 1-year after infection anti-SARS-CoV-2 humoral antibody antibody durability. caused CD4 CD8 CD8 T cell CD8 T cell responses Cell cellular immunity central memory circulating antibodies circulating antibody Cohort convalescent COVID-19 COVID-19 convalescent COVID-19 patient disease disease severity effective IgG level immune Immune components immune memory immune protection Immunity induce Infection information Kinetics maintain memory memory B memory B cell Memory responses memory T cells omicron Omicron variant peptide peptide pool persistence protective immunity provide RBD IgG Re-infection recorded response reveal SARS-CoV-2 SARS-CoV-2 circulating antibodies SARS-COV-2 infection subject Symptom T cell T cell response T cell responses T cells tested the RBD the SARS-CoV-2 variant
[DOI] 10.1080/22221751.2022.2049984 PMC 바로가기 [Article Type] Article